Bausch Health Companies Inc. vs MannKind Corporation: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Bausch Health Companies Inc. and MannKind Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Bausch Health's SG&A expenses have seen a steady increase, peaking at approximately $2.9 billion in 2023, marking a 44% rise from 2014. This growth reflects their aggressive expansion and strategic investments. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a slight increase of about 19% over the same period, reaching around $94 million in 2023.

These trends highlight the differing strategies of these companies: Bausch Health's focus on scaling operations versus MannKind's more conservative approach. Investors and analysts should consider these financial trajectories when evaluating potential growth and risk.